Fusion Antibodies plc
FAB.L · LSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | £1,965 | £1,136 | £2,901 | £4,799 |
| % Growth | 73% | -60.8% | -39.5% | – |
| Cost of Goods Sold | £1,535 | £1,401 | £2,699 | £3,082 |
| Gross Profit | £430 | -£265 | £202 | £1,717 |
| % Margin | 21.9% | -23.3% | 7% | 35.8% |
| R&D Expenses | £191 | £254 | £806 | £699 |
| G&A Expenses | £1,862 | £2,247 | £3,051 | £3,029 |
| SG&A Expenses | £1,860 | £1,773 | £2,229 | £2,350 |
| Sales & Mktg Exp. | -£2 | -£474 | -£822 | -£679 |
| Other Operating Expenses | £158 | £216 | £0 | £0 |
| Operating Expenses | £2,209 | £2,243 | £3,035 | £3,049 |
| Operating Income | -£1,779 | -£2,288 | -£2,833 | -£1,332 |
| % Margin | -90.5% | -201.4% | -97.7% | -27.8% |
| Other Income/Exp. Net | £2 | -£1 | -£1 | -£8 |
| Pre-Tax Income | -£1,777 | -£2,289 | -£2,859 | -£1,333 |
| Tax Expense | £64 | -£63 | -£263 | -£133 |
| Net Income | -£1,713 | -£2,226 | -£2,596 | -£1,200 |
| % Margin | -87.2% | -196% | -89.5% | -25% |
| EPS | -0.018 | -0.04 | -0.1 | -0.046 |
| % Growth | 55.4% | 59.8% | -115.6% | – |
| EPS Diluted | -0.018 | -0.04 | -0.1 | -0.046 |
| Weighted Avg Shares Out | 95,880 | 55,556 | 26,015 | 25,946 |
| Weighted Avg Shares Out Dil | 95,879 | 55,556 | 26,015 | 25,946 |
| Supplemental Information | – | – | – | – |
| Interest Income | £5 | £3 | £3 | £1 |
| Interest Expense | £3 | £5 | £4 | £9 |
| Depreciation & Amortization | £102 | £219 | £372 | £751 |
| EBITDA | -£1,624 | -£2,065 | -£2,483 | -£573 |
| % Margin | -82.6% | -181.8% | -85.6% | -11.9% |